Company Filing History:
5 out of 115 
5 out of 517 
2 out of 192 
Years Active: 2018-2021
Title: Johanna Schuitemaker: Innovator in HIV Research
Introduction
Johanna Schuitemaker is a prominent inventor based in Amstelveen, Netherlands. She has made significant contributions to the field of immunology, particularly in the development of vaccines against human immunodeficiency virus (HIV) infection. With a total of five patents to her name, her work has been pivotal in advancing our understanding of protective immunity.
Latest Patents
Schuitemaker's latest patents include innovative compositions and methods for inducing protective immunity against HIV infection. One of her notable patents describes heterologous vaccine combinations that utilize adenovirus 26 vectors for priming immunization, along with isolated HIV antigenic polypeptides and MVA vectors for boosting immunization. This approach has shown promise in inducing strong protective immunity against various clades of HIV. Another significant patent outlines methods for inducing an immune response in HIV-infected subjects undergoing antiretroviral treatment. This method involves administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine that encodes mosaic HIV antigens.
Career Highlights
Throughout her career, Schuitemaker has worked with esteemed organizations such as Janssen Vaccines & Prevention B.V. and Beth Israel Deaconess Medical Center, Inc. Her research has been instrumental in the development of effective strategies for combating HIV, showcasing her dedication to public health and scientific advancement.
Collaborations
Schuitemaker has collaborated with notable colleagues in her field, including Dan H. Barouch and Maria Grazia Pau. These partnerships have further enriched her research and contributed to the success of her innovative projects.
Conclusion
Johanna Schuitemaker's work in HIV research exemplifies the impact of innovation in the medical field. Her patents and collaborations highlight her commitment to advancing vaccine development and improving health outcomes for individuals affected by HIV.